Rosario Pedro Weslley, Calsolari Maria Regina
Santa Casa de Belo Horizonte, MG, Brazil.
Endocrinology Service, Santa Casa de Belo Horizonte, MG, Brazil.
Arq Bras Endocrinol Metabol. 2014 Nov;58(8):812-6. doi: 10.1590/0004-2730000003350. Epub 2014 Nov 1.
To determine whether the currently recommended therapy for papillary thyroid carcinoma (PTC) that show no classical factors indicating a poor prognosis is also effective in cases with a family history of this tumor.
Forty-two patients were studied; 10 were submitted to lobectomy and 32 to total thyroidectomy, including 23 without lymph node dissection and 9 with lymph node dissection. None of the patients received radioiodine or was maintained under TSH suppression.
No case of recurrence was detected by imaging methods and there was no increase in thyroglobulin or antithyroglobulin antibodies during follow-up (24 to 72 months).
The treatment usually recommended for patients with PTC does not need to be modified in the presence of a family history of this tumor if no factors indicating a poor prognosis are present (tumor ≤2 cm, non-aggressive histology, no extensive extrathyroid invasion or important lymph node involvement, complete tumor resection, no evidence of persistent disease after surgery).
确定目前推荐用于无提示预后不良经典因素的乳头状甲状腺癌(PTC)的治疗方法,对于有该肿瘤家族史的病例是否也有效。
研究了42例患者;10例行叶切除术,32例行全甲状腺切除术,其中23例未行淋巴结清扫,9例行淋巴结清扫。所有患者均未接受放射性碘治疗,也未在促甲状腺激素(TSH)抑制状态下维持治疗。
通过影像学方法未检测到复发病例,随访期间(24至72个月)甲状腺球蛋白或抗甲状腺球蛋白抗体也未升高。
如果不存在提示预后不良的因素(肿瘤≤2 cm、组织学无侵袭性、无广泛甲状腺外侵犯或重要淋巴结受累、肿瘤完全切除、术后无持续性疾病证据),对于有PTC家族史的患者,通常推荐的治疗方法无需改变。